Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis.

Ther Adv Med Oncol · 2025 · PMC12089717 · PMID 40396122

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In terms of OS, the regimen of “CT + AMI” ranked the best, followed by “CT + IVO.” However, the comparisons of OS among different regimens did not reach statistical significance, possibly due to immature data.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.